Skip to content
Olio Labs logo

Olio Labs

Olio Labs is a YC Summer 2023 (S23) company. Based in Remote. Team of 5.

About Olio Labs

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Olio Labs develops AI-driven combination therapeutics for complex diseases, starting with obesity. Where conventional drugs target one or two proteins, Olio Labs models thousands of interacting proteins simultaneously and searches trillions of drug combinations to identify candidates with greater efficacy and fewer side effects than existing GLP-1 treatments like semaglutide. The work replaces traditional trial-and-error combination screening in early-stage drug discovery.

From the Y Combinator listing

How Olio Labs describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Combination therapeutics for the world's toughest diseases

Olio labs uses AI to develop combination therapeutics that consider the thousands of interacting proteins in your body rather than targeting just one or two. Their lead combinations target obesity and are more effective with fewer side effects than Ozempic, the fastest growing drug of all time. Their custom ML built from real-world expertise and cutting edge AI searches trillions of combinations to find the perfect one.

Facts

Industry
Healthcare / Healthcare -> Drug Discovery and Delivery
Location
Remote
Team size
5
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works